A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Primary objective: To evaluate the pharmacokinetic effects of fluzoparib on caffeine,
S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with recurrent
ovarian cancer.
Secondary objective: To evaluate the safety of single dose of fluzoparib, caffeine,
S-warfarin, omeprazole, midazolam, repaglinide and bupropion or fluzoparib in combination
with caffeine, S-warfarin, omeprazole, midazolam, repaglinide and bupropion in patients with
recurrent ovarian cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Bupropion Caffeine Midazolam Omeprazole Repaglinide Vitamin K Warfarin